-
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639 ·
Phase: Not specified ·
Ages: 14 Years to 37 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 55 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
NCT06290401 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 13 Years to 21 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082 ·
Phase: Phase 3 ·
Ages: 12 Years to 100 Years ·
Sex: All (male and female)
· Pennsylvania: Easton, Philadelphia
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
NCT06665997 ·
Phase: Phase 4 ·
Ages: 18 Years to 50 Years ·
Sex: Female
· Pennsylvania: Philadelphia
-
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
NCT06941389 ·
Phase: Not specified ·
Ages: 3 Years to 20 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Cutaneous Hydration Assessment in SCD
NCT05210114 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
NCT04528355 ·
Phase: Not specified ·
Ages: 2 Months to 60 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
NCT04109820 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
NCT06374238 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 16 Years to 30 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
RH Genotype Matched RBC Transfusions
NCT04156893 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
NCT06385886 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415 ·
Phase: Phase 2 ·
Ages: 2 Months to 55 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822 ·
Phase: Phase 4 ·
Ages: 6 Months to 100 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
NCT07252050 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 45 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 ·
Phase: Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease
NCT07316478 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT03653338 ·
Phase: Phase 1, Phase 2 ·
Ages: 5 Years to 40 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
NCT06260891 ·
Phase: Phase 2 ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia